Daniel E. Stepan

3.9k total citations · 4 hit papers
35 papers, 2.8k citations indexed

About

Daniel E. Stepan is a scholar working on Molecular Biology, Oncology and Reproductive Medicine. According to data from OpenAlex, Daniel E. Stepan has authored 35 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 10 papers in Oncology and 9 papers in Reproductive Medicine. Recurrent topics in Daniel E. Stepan's work include Cancer Immunotherapy and Biomarkers (9 papers), Ovarian cancer diagnosis and treatment (8 papers) and Renal cell carcinoma treatment (6 papers). Daniel E. Stepan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), Ovarian cancer diagnosis and treatment (8 papers) and Renal cell carcinoma treatment (6 papers). Daniel E. Stepan collaborates with scholars based in United States, Spain and France. Daniel E. Stepan's co-authors include Matthew H. Taylor, Corina E. Dutcus, Vicky Makker, Robert Shumaker, Drew Rasco, Yu-Nien Sun, Emmett V. Schmidt, Jane Wu, Lori J. Wirth and Steven I. Sherman and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Daniel E. Stepan

34 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Micafungin versus Fluconazole for Prophylaxis against Invasive Fungal Infections during Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation

2004 526 citations V. Ratanatharathorn, Daniel E. Stepan et al. Clinical Infectious Diseases profile →
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial

2019 360 citations Vicky Makker, Drew Rasco et al. The Lancet Oncology profile →
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

2020 359 citations Vicky Makker, Matthew H. Taylor et al. Journal of Clinical Oncology profile →
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors

2020 306 citations Matthew H. Taylor, Chung‐Han Lee et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Daniel E. Stepan

Since Specialization

Citations

This map shows the geographic impact of Daniel E. Stepan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel E. Stepan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel E. Stepan more than expected).

Fields of papers citing papers by Daniel E. Stepan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel E. Stepan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel E. Stepan. The network helps show where Daniel E. Stepan may publish in the future.

Co-authorship network of co-authors of Daniel E. Stepan

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel E. Stepan. A scholar is included among the top collaborators of Daniel E. Stepan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel E. Stepan. Daniel E. Stepan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Coarse-grained mathematical models for studying mechanical properties of the DNA 2025 ·Biophysical Reviews ·Daniel E. Stepan, (unknown), (unknown)	0
2	Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer breakdown → 2020 ·Journal of Clinical Oncology ·Vicky Makker, Matthew H. Taylor, Carol Aghajanian, Ana Oaknin, James W. Mier, Allen Lee Cohn, Margarita Romeo, Raquel Bratos, Marcia S. Brose, Christopher DiSimone, Mark Messing, Daniel E. Stepan, Corina E. Dutcus, Jane Wu, Emmett V. Schmidt, Robert Orlowski, Perminder S. Sachdev, Robert Shumaker, Antonio Casado	359
3	Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors breakdown → 2020 ·Journal of Clinical Oncology ·Matthew H. Taylor, Chung‐Han Lee, Vicky Makker, Drew Rasco, Corina E. Dutcus, Jane Wu, Daniel E. Stepan, Robert Shumaker, Robert J. Motzer	306
4	Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: Final analysis of a multicentre, open-label, single-arm, phase 2 trial 2020 ·Gynecologic Oncology ·(unknown), (unknown), Nicholas J. Vogelzang, Marcia S. Brose, Allen Lee Cohn, J W Mier, Christopher DiSimone, David M. Hyman, Daniel E. Stepan, Corina E. Dutcus, Emmett V. Schmidt, (unknown), Perminder S. Sachdev, Robert Shumaker, (unknown), Matthew H. Taylor	2
5	Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial breakdown → 2019 ·The Lancet Oncology ·Vicky Makker, Drew Rasco, Nicholas J. Vogelzang, Marcia S. Brose, Allen Lee Cohn, James W. Mier, Christopher Di Simone, David M. Hyman, Daniel E. Stepan, Corina E. Dutcus, Emmett V. Schmidt, Matthew Guo, Perminder S. Sachdev, Robert Shumaker, Carol Aghajanian, Matthew H. Taylor	360
6	Phase Ib/II trial of lenvatinib plus pembrolizumab in urothelial cancer. 2019 ·Journal of Clinical Oncology ·Nicholas J. Vogelzang, Carlos A. Encarnacion, Allen Lee Cohn, Christopher DiSimone, Drew Rasco, Donald Richards, Matthew H. Taylor, Corina E. Dutcus, Daniel E. Stepan, Robert Shumaker, Matthew Guo, Emmett V. Schmidt, James W. Mier	9
7	A phase Ib/II trial of lenvatinib plus pembrolizumab in non-small cell lung cancer. 2019 ·Journal of Clinical Oncology ·Marcia S. Brose, Nicholas J. Vogelzang, Christopher DiSimone, Sharad Jain, Donald Richards, Carlos A. Encarnacion, Drew Rasco, Robert Shumaker, Corina E. Dutcus, Daniel E. Stepan, Matthew Guo, Emmett V. Schmidt, Matthew H. Taylor	9
8	Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis 2019 ·Annals of Oncology ·Chung‐Han Lee, Amishi Y. Shah, Vicky Makker, Matthew H. Taylor, David R. Shaffer, James J. Hsieh, Allen Lee Cohn, Christopher DiSimone, (unknown), Drew Rasco, (unknown), Donald Richards, Daniel E. Stepan, Corina E. Dutcus, Jane Wu, Emmett V. Schmidt, Rodolfo F. Perini, Robert J. Motzer	3
9	A phase 2 trial of lenvatinib 18 mg versus 14 mg once daily (QD) in combination with everolimus (5 mg QD) in renal cell carcinoma (RCC) after 1 prior VEGF-targeted treatment. 2018 ·Journal of Clinical Oncology ·Hilary Glen, Javier Puente, Daniel Yick Chin Heng, Sun Young Rha, Di Li, Daniel E. Stepan, Corina E. Dutcus, Sumanta K. Pal	3
10	A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with renal cell carcinoma 2017 ·Annals of Oncology ·Chi‐Hang Lee, Vicky Makker, (unknown), Matthew H. Taylor, Corina E. Dutcus, Robert Shumaker, Emmett V. Schmidt, Daniel E. Stepan, (unknown), Robert J. Motzer	22
11	Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection 2011 ·Cancer Chemotherapy and Pharmacology ·Jianfeng Lü, Erik Rasmussen, Beth Y. Karlan, Ignace Vergote, Lynn Navale, (unknown), (unknown), Daniel E. Stepan, David M. Weinreich, Yu‐Nien Sun	34
12	Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer 2011 ·Journal of Clinical Oncology ·Beth Y. Karlan, Amit M. Oza, Gary Richardson, Diane Provencher, Vincent Hansen, Martin Buck, Setsuko K. Chambers, Prafull Ghatage, Charles H. Pippitt, John V. Brown, Allan Covens, Raj Nagarkar, Margaret Davy, Charles A. Leath, Hoa Nguyen, Daniel E. Stepan, David M. Weinreich, Marjan Tassoudji, Yu-Nien Sun, Ignace Vergote	171
13	Phase Ib study of AMG 386 combined with either pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with advanced ovarian cancer. 2010 ·Journal of Clinical Oncology ·(unknown), Joseph W. Leach, Sidney Scudder, (unknown), Charles H. Pippitt, Anderley Gordon, Nadeeshani Nanayakkara, Eunju Hurh, Daniel E. Stepan, Russell J. Schilder	5
14	Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer 2009 ·Journal of Clinical Oncology ·Martin Schlumberger, Rossella Elisei, Lars Bastholt, Lori J. Wirth, Renato Martins, Laura D. Locati, Barbara Jarząb, Furio Pacini, Chantal Daumerie, Jean-Pierre Droz, Michael Eschenberg, Yu-Nien Sun, Todd Juan, Daniel E. Stepan, Steven I. Sherman	257
15	A modeling framework to simulate motesanib efficacy in thyroid cancer 2009 ·Journal of Clinical Oncology ·Laurent Claret, Jianfeng Lu, Yu Sun, Daniel E. Stepan, René Bruno	1
16	Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer 2008 ·New England Journal of Medicine ·Steven I. Sherman, Lori J. Wirth, Jean-Pierre Droz, Michael Hofmann, Lars Bastholt, Renato Martins, Lisa Licitra, Michael Eschenberg, Yu-Nien Sun, Todd Juan, Daniel E. Stepan, Martin Schlumberger	363
17	Safety Profile of AMG 531 in Healthy Volunteers and in Thrombocytopenic Patients with Immune Thromobocytopenic Purpura. 2005 ·Blood ·Daniel E. Stepan, (unknown), Reggie Kelly, (unknown), Chien‐Feng Chen, Janet L. Nichol	6
18	Micafungin versus Fluconazole for Prophylaxis against Invasive Fungal Infections during Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation breakdown → 2004 ·Clinical Infectious Diseases ·(unknown), V. Ratanatharathorn, Daniel E. Stepan, Carole B. Miller, Jeffrey H. Lipton, David H. Vesole, Nancy Bunin, Donna A. Wall, J. Hiemenz, Yoichi Satoi, (unknown), Thomas J. Walsh	526
19	Central Nervous System Failure in Patients with Chronic Myelogenous Leukemia Lymphoid Blast Crisis and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with Imatinib (STI-571) 2003 ·Leukemia & lymphoma ·José F. Leis, Daniel E. Stepan, Peter Curtin, J. Ford, Bin Peng, (unknown), Brian Druker, Richard T. Maziarz	82
20	Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host disease 1998 ·Biology of Blood and Marrow Transplantation ·Eileen Smith, Irena Sniecinski, Andrew Dagis, Pablo Parker, David S. Snyder, Anthony S. Stein, Auayporn Nademanee, Margaret O’Donnell, Arturo Molina, G. Schmidt, Daniel E. Stepan, Neena Kapoor, Joyce C. Niland, Stephen J. Forman	65

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact